Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.

Slični predmeti

• PSA is dead, long live PSA.
  od: Vickers, A, i dr.
  Izdano: (2012)
• Erratum: Evaluation of molecular forms of PSA and human kallikrein 2 in predicting biochemical failure following radical prostatectomy (International Journal of Cancer (2009) 125 (659-663) DOI:10.1002/ijc.23983)
  od: Wenske, S, i dr.
  Izdano: (2010)
• Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
  od: Steuber, T, i dr.
  Izdano: (2006)
• Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
  od: Ulmert, D, i dr.
  Izdano: (2008)
• Can PSA velocity predict risk of death in men with prostate cancer?
  od: Lilja, H, i dr.
  Izdano: (2007)